Skip to main content

Table 3 Association between pathological features and either/or co-expression of mesothelin and CA125

From: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Parameter Mesothelin Expression CA125 Expression Co-Expression of mesothelin and CA125
Positive Negative p-value Positive Negative p-value Positive Negative p-value
(n = 171) (n = 314) (n = 368) (n = 117) (n = 167) (n = 318)
Age
  ≥ 60 99 (58%) 153 (49%) 0.053 188 (51%) 64 (55%) 0.52 97 (58%) 155 (49%) 0.055
  <  60 72 (42%) 161 (51%)   180 (49%) 53 (45%)   70 (42%) 163 (51%)  
FIGO stage
 I and II 124 (73%) 242 (77%) 0.27 280 (76%) 86 (74%) 0.62 120 (72%) 246 (77%) 0.18
 III and IV 47 (27%) 72 (23%)   88 (24%) 31 (26%)   47 (28%) 72 (23%)  
Depth of myometrial invasion
  ≥ 1/2 71 (42%) 99 (32%) 0.028 128 (35%) 42 (36%) 0.82 71 (42%) 99 (31%) 0.016
  < 1/2 100 (58%) 215 (68%)   240 (65%) 75 (64%)   96 (58%) 219 (69%)  
Lymphovascular invasion
 Yes 85 (50%) 123 (39%) 0.027 156 (42%) 52 (44%) 0.74 84 (50%) 124 (39%) 0.02
 No 86 (50%) 191 (61%)   212 (58%) 65 (56%)   83 (50%) 194 (61%)  
Cervical invasion
 Yes 27 (16%) 66 (21%) 0.18 71 (19%) 22 (19%) 1.0 27 (16%) 66 (21%) 0.27
 No 144 (84%) 248 (79%)   297 (81%) 95 (81%)   140 (84%) 252 (79%)  
Ovarian metastasis
 Yes 14 (8%) 16 (5%) 0.23 24 (7%) 6 (5%) 0.66 14 (8%) 16 (5%) 0.16
 No 157 (92%) 298 (95%)   344 (93%) 111 (95%)   153 (92%) 302 (95%)  
Lymph node metastasis
 Yes 27 (16%) 38 (12%) 0.35 50 (14%) 15 (13%) 0.93 27 (16%) 38 (12%) 0.30
 No 111 (65%) 223 (71%)   254 (69%) 80 (68%)   108 (65%) 226 (71%)  
 Unevaluated 33 (19%) 53 (17%)   64 (17%) 22 (19%)   32 (19%) 54 (17%)  
Distant metastasis
 Yes 17 (10%) 22 (7%) 0.29 27 (7%) 12 (10%) 0.33 17 (10%) 22 (7%) 0.22
 No 154 (90%) 292 (93%)   341 (93%) 105 (90%)   150 (90%) 296 (93%)  
Peritoneal cytology
 Yes 37 (22%) 52 (17%) 0.17 71 (19%) 18 (15%) 0.41 37 (22%) 52 (17%) 0.17
 No 134 (78%) 262 (83%)   297 (81%) 99 (85%)   130 (78%) 266 (83%)  
Adjuvant therapy
 Yes 99 (58%) 170 (54%) 0.44 201 (55%) 68 (58%) 0.52 98 (59%) 171 (54%) 0.33
 No 72 (42%) 144 (46%)   167 (45%) 49 (42%)   69 (41%) 147 (46%)  
  1. CA125 cancer antigen 125, FIGO International Federation of Obstetrics and Gynecology